Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The patients eligible for this study are those diagnosed with glioblastoma or gliosarcoma who
have recently undergone surgery and who have not been treated with radiation therapy or
chemotherapy. This is called a phase II study. The purpose of the phase II study is to
determine how effective Tarceva plus Temodar plus radiation is in controlling the growth of
glioblastoma and gliosarcoma. All patients will receive radiation and Temodar plus Tarceva.
There is no "placebo" drug.